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Gestational diabetes mellitus (GDM) is defined as glucose 
intolerance with onset or first recognition during pregnancy.[1] 
The prevalence of GDM has significantly increased over the past 
20 years,[2] and in 2017 the International Diabetes Federation (IDF) 
estimated that ~14% of pregnant women are affected by GDM, 
depending on the diagnostic criteria used and population studied.[3] 
The World Health Organization (WHO) classifies pre-existing 
diabetes or newly diagnosed type 1 or type 2 diabetes as severe 
hyperglycaemia during pregnancy, while GDM represents a milder 
form of hyperglycaemia that occurs in the latter half of pregnancy 
and usually resolves after delivery.[4] Without appropriate glucose 
management, GDM is associated with perinatal complications and 
an increased risk of future metabolic disease in mothers and their 
offspring. 
The early detection and treatment of GDM are effective in 
preventing these adverse outcomes; therefore, universal screening 
and diagnosis of GDM are widely advocated as a strategy to 
promote appropriate treatment and improve pregnancy outcomes. 
The oral glucose tolerance test (OGTT) conducted at 24 - 28 weeks of 
gestation is currently considered the gold standard for the diagnosis 
of GDM.[5] However, the test is cumbersome to conduct, as well 
as time consuming, expensive and unfeasible in many low- and 
middle-income countries, resulting in many countries using risk 
factor-based selective screening. The lack of uniformity in GDM 
diagnosis and variations in clinical practice hamper its early detection 
and management, which negatively affect maternal and child health. 
Therefore, the identification of simple, cost-effective, sensitive and 
specific biomarkers, which do not require fasting and multiple 
sampling, may become potential screening and diagnostic tools and 
have become a major focus in GDM research. This review describes 
the major GDM screening and diagnostic strategies used worldwide, 
including novel screening and diagnostic methods that are being 
explored. It highlights the varied screening and diagnostic strategies 
currently employed in South Africa (SA). We also discuss challenges 
associated with these strategies and offer recommendations for future 
research. 
Screening tests
The terms screening and diagnosis are often confusingly used 
interchangeably.[6] Screening tests identify asymptomatic GDM 
in apparently healthy pregnant women, facilitating diagnosis and 
management.[7] A negative screening test obviates the need for 
the cumbersome OGTT, the gold standard for GDM diagnosis, 
which is costly and is associated with multiple sampling, nausea 
and vomiting. Currently, screening for GDM is done by using 
traditional risk factors,[8] the 50 g glucose challenge test (GCT) 
or an OGTT.[6] A number of other novel screening tests are being 
explored, including fasting plasma glucose,[9] glycated haemoglobin 
(HbA1c),[10] cytokines[11] and molecular biomarkers,[12] which are 
discussed in more detail below. Screening for traditional risk factors 
remains the cornerstone of screening strategies in low- and middle-
income countries due to costs and ease. However, several studies[8,13-15] 
have reported that risk factors have poor predictive value and fail to 
identify a large percentage of women with GDM, thus limiting their 
use. Adam et al.[8] reported that risk factors failed to identify ~10.6% of 
pregnant women with GDM in SA. The GCT is commonly used to screen 
for GDM in the USA and involves administering a 50 g glucose load 
to pregnant women at 24 - 28 weeks’ gestation, irrespective of fasting. 
If their 1 h plasma glucose concentrations exceed predetermined 
cut-off values, usually 7.2 mmol/L or 7.8 mmol/L, they are referred 
for GDM diagnosis. In 2010, the International Association of 
Diabetes in Pregnancy Study Groups (IADPSG) advocated for ‘no 
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screening’ or ‘universal testing’, where all 
pregnant women undergo the diagnostic 
75 g OGTT at 24 - 28 weeks of gestation.[16] 
Furthermore, the IADPSG decreased the 
threshold for diagnosing GDM (Table 1). 
These recommendations were based on 
findings from the Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) study 
that showed a linear correlation between 
maternal blood glucose concentrations and 
adverse pregnancy outcomes, even at glucose 
concentrations previously considered 
normal.[17] The HAPO study assessed glucose 
concentrations and pregnancy complications 
in 23 316 pregnant women across 9 countries; 
therefore, the IADPSG considered this 
evidence sufficient to alter the diagnostic 
criteria for GDM. A few years later, the 
WHO endorsed the IADPSG universal 
testing strategy, but remains sceptical owing 
to poor quality of evidence, increased costs 
and the possibility of overdiagnosis.[18] 
Globally, there are no accepted screening 
criteria for GDM, and universal testing for 
diagnosing GDM remains the recommended 
strategy, although its implementation varies 
across countries and institutions. 
Diagnosis
The OGTT is the gold standard for diag -
nosis of GDM. However, its use is not 
standardised worldwide and varies according 
to availability and access of standardised 
laboratories, resources, cost and GDM risk. 
The main issues of contention are whether 
a one-step or two-step procedure, which 
includes prior screening, is used, the glucose 
load (75 g or 100 g), duration of test (2 h 
or 3 h), glucose cut-off values, and whether 
diagnosis is based on one or two high glucose 
values.[18] GDM diagnosis has evolved 
considerably over the years, with older 
criteria based mainly on managing long-
term health outcomes, while more recent 
criteria focus on adverse perinatal outcomes. 
The landmark screening and diagnostic 
criteria for GDM are shown in Fig. 1. In 
1964, O’Sullivan and Mahan[19] proposed a 
two-step approach, which involved screening 
with the GCT, followed by a confirmatory 
100 g 3 h OGTT in women who tested 
positive for screening. The National Diabetes 
Data Group (NDDG)[20] and Carpenter and 
Coustan[21] revised these criteria in 1979 and 
1984, respectively, correcting for the higher 
glucose concentrations in plasma compared 
with venous blood that was originally used 
by O’Sullivan and Mahan.[19] In 1985, the 
WHO recommended that a 75 g 2 h OGTT 
be performed to diagnose GDM, using the 
same thresholds as those for diagnosing 
diabetes in non-pregnant women.[22] In 
1999, the WHO revised their diagnostic 
criteria for GDM to include impaired 
glucose tolerance (IGT) and diabetes.[23] 
The American Diabetes Association (ADA) 
adopted the Carpenter and Coustan[21] 
criteria and recommended testing for GDM 
at 24 - 28 weeks’ gestation using either a one-
O'Sullivan and Mahan[19]
2-step 100 g 3 h OGTT
FPG ≥5.0 mmol/L
1 h ≥9.2 mmol/L
2 h ≥8.1 mmol/L
3 h ≥6.9 mmol/L
Carpenter and Coustan[21]
2-step 100 g 3 h OGTT
FPG ≥5.3 mmol/L
1 h ≥10.0 mmol/L
2 h ≥8.6 mmol/L
3 h ≥7.8 mmol/L
Latin American Diabetes 
Association[25]
2-step 75 g 2 h OGTT
FPG ≥5.5 mmol/L
2 h ≥7.8 mmol/L
National Diabetes Data Group[20]
2-step 100 g 3 h OGTT
FPG ≥5.8 mmol/L
1 h ≥10.6 mmol/L
2 h ≥9.2 mmol/L
3 h ≥8.1 mmol/L
American Diabetes Association[24]
2-step 100 g 3 h OGTT
1 h ≥10.0 mmol/L
2 h ≥8.6 mmol/L
3 h ≥7.8 mmol/L or ≥7.2  mmol/L
International Association of Diabetes 
in Pregnancy Study Groups[16]
1-step 75 g 2 h OGTT
FPG ≥5.1 mmol/L
1 h ≥10.0 mmol/L
2 h ≥8.5 mmol/L
National Institute for Health and 
Care Excellence[26] 
1-step 75 g 2 h OGTT
FPG ≥5.6 mmol/L
2 h ≥7.8 mmol/L
1964
1982
1999
2008
2013
1979
1985
2004
2010
2015
World Health Organization[23]
1-step 75 g 2 h OGTT
Impaired glucose tolerance
   FPG <7.0 mmol/L
   2 h ≥7.8 mmol/L
Diabetes
   FPG ≥7.0 mmol/L
   2 h glucose ≥11.1 mmol/L
World Health Organization 
(revised)[27]
1-step 75 g 2 h OGTT
FPG ≥5.1 mmol/L
1 h ≥10.0 mmol/L
2 h ≥8.6 mmol/L
World Health Organization[22]
1-step 75 g 2 h OGTT
Diabetes
   FPG ≤7.8 mmol/L
   2 h glucose ≥11.1 mmol/L
Fig. 1. The evolution of gestational diabetes mellitus screening and diagnosis between 1964 and 2015. 
(FPG = fasting plasma glucose; OGTT = oral glucose tolerance test.)
Table 1. Diagnostic criteria for gestational diabetes mellitus commonly used in South Africa
Organisation
Glucose 
load, g
0 h glucose, 
mmol/L
1 h glucose, 
mmol/L
2 h glucose, 
mmol/L
3 h glucose, 
mmol/L Values for diagnosis
IADPSG/WHO/FIGO 75 5.1 10 8.5 - ≥1
NICE 75 5.6 - 7.8 - ≥1
ACOG 100 5.3 10 8.6 7.8 ≥2
WHO 1999 75 7.0 - 7.8 - ≥1
IADPSG = International Association of Diabetes in Pregnancy Study Groups; WHO = World Health Organization; FIGO = Federation of Gynaecology and Obstetrics;  
NICE = National Institute for Health and Care Excellence; ACOG = American College of Obstetricians and Gynecologists.
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step approach with the 100 g OGTT or a two-step procedure with the 
GCT, followed by a diagnostic 100 g OGTT.[24] In the final report of 
the Pan American Conference on Diabetes and Pregnancy, the Latin 
American Diabetes Association (LADA) criteria were proposed for 
the diagnosis of GDM in selected countries of South America, using 
a two-step approach with a 75 g 2 h OGTT.[25] In 2010, as previously 
described, the IADPSG proposed universal testing, where a one-step 
75 g 2 h OGTT is conducted for all pregnant women at 24 - 28 weeks’ 
gestation.[5] In 2013, the WHO revised their criteria and endorsed 
those of the IADPGS.[4] The National Institute for Health and Care 
Excellence (NICE) criteria are based on the WHO 1999 criteria, 
where GDM is diagnosed as IGT using the 75 g 2 h OGTT.[26] They 
have not adopted the new recommended IADPSG/WHO 2013 diag -
nostic criteria, as evidence suggests relatively small differences in 
clinical outcomes and increased cost implications.[27] Currently, 
the International Federation of Gynecology and Obstetrics (FIGO) 
guidelines[1] recommend the use of a glucometer for point-of-care 
diagnosis of GDM in limited-resource settings due to its low cost, 
ease of use and ability to diagnose and treat GDM at the earliest 
possible opportunity. However, a study investigating the performance 
of the glucometer diagnosis of GDM compared with the gold 
standard laboratory test showed poor correlation and reproducibility 
when GDM was diagnosed using the FIGO criteria.[28]
Novel screening and diagnostic 
strategies
Glucose
Measurement of fasting glucose concentrations has shown promise 
as a screening[29] and diagnostic test;[8,30] however, the test requires 
pregnant women to be in a fasted state and return to the clinic to 
obtain their laboratory results.[9] Measurement of random glucose and 
HbA1c levels obviates the need for fasting and has been explored as 
alternative screening and diagnostic tests.[31] HbA1c, a measurement 
of the amount of glucose bound to haemoglobin, is currently the 
gold standard for long-term blood glucose monitoring. However, it 
is affected by factors such as ethnicity, anaemia, haemodilation or 
other blood disorders that hamper its accuracy as a diagnostic tool 
for GDM.[31-33] Therefore, although these tests are convenient, fast, 
simple, inexpensive and can be done at point of care, the results 
are inconsistent, with low sensitivity and specificity, and have been 
unsuccessful to date. 
Other novel strategies investigated in the SA population include 
the ‘breakfast test’– a non-standardised glucose load administered to 
pregnant women – instead of the OGTT.[34] Because of the variability 
in carbohydrate content with a non-standardised glucose load,[35] 
the breakfast test was revised to include a standardised carbohydrate 
content that is equivalent to the 75 g OGTT. Marais et al.[34] reported 
a correlation between blood glucose values obtained using the 
designed breakfast test and values obtained using the OGTT. These 
and other results suggest that a standardised breakfast test that is 
more palatable than the OGTT may offer an alternative method for 
assessing hyperglycaemia during pregnancy.[36-38]
Serum proteins
Adaptation to metabolic stress during pregnancy is reflected by 
changes in the expression of maternal proteins. These proteins are 
readily detected in plasma or serum and have recently attracted 
considerable interest as potential screening and diagnostic proteins 
for GDM. Several studies have reported on the potential of maternal 
plasma or serum biomarkers, such as adiponectin, sex hormone-
binding globulin (SHBG), C-reactive protein (CRP) and glycosylated 
fibronectin, as biomarkers of GDM.[39-41] Nanda et al.[39] reported 
that maternal serum adiponectin and SHBG levels at 11 - 13 weeks 
of gestation were lower in women with GDM than in controls. 
Similarly, Smirnakis et al.[41] reported lower levels of serum SHBG 
and higher levels of CRP during the first and second trimesters in 
pregnant women who subsequently developed GDM. Furthermore, 
glycosylated fibronectin, adiponectin, CRP and human placental 
lactogen (hPL) concentrations at 5 - 13 weeks of gestation were shown 
to be associated with GDM.[40] Together, these studies demonstrate 
that maternal proteins represent a promising first- and second-
trimester screening test to identify women at risk of developing 
GDM. Further prospective studies are required to investigate the 
clinical applicability of these biomarkers. 
Genetics
Variants in genes regulating glucose homeostasis are increasingly 
being implicated in the pathogenesis of GDM and thus present 
candidates for biomarkers of disease pathophysiology.[42] To date, 
genetic studies have identified 8 genes commonly associated with the 
development of GDM in ≥2 independent populations. While genetic 
variants have been identified in other genes associated with GDM, 
these were only demonstrated in single populations.[12] The genes 
identified in ≥2 independent populations include transcription factor 
7-like 2 (TCF7L2), adiponectin (ADIPOQ), melatonin-receptor 
1B gene (MTNR1B), glucokinase (GCK), glucokinase regulator 
(GCKR), fat mass and obesity-associated (FTO), insulin-receptor 
substrate 1 (IRS1) and potassium voltage-gated channel subfamily 
Q member 1 (KCNQ). Due to variation across different populations, 
further studies are needed to confirm the association between risk 
alleles and GDM. Further analysis in diverse ethnic groups is required 
to examine whether these risk variants can be used as biomarkers to 
predict the development of GDM. Despite the association between 
genetics and GDM, the important role of the environment in GDM 
susceptibility is increasingly being recognised.
Epigenetics
Epigenetics is defined as changes in gene expression that occur 
without changes in the underlying DNA sequence.[43] These changes 
reflect gene-environment interactions and are increasingly being 
implicated in the pathophysiology of metabolic diseases.[44,45] 
Epigenetic mechanisms include DNA methylation, chromatin and 
histone modifications, and non-coding RNAs such as microRNAs 
(miRNAs). DNA methylation is the most widely studied and best 
characterised epigenetic mechanism, and refers to the addition of a 
methyl group to the fifth carbon position of a cytosine nucleotide, 
often leading to transcriptional repression.[46] DNA methylation 
plays a key role in regulating genes involved in metabolic adaptation 
during pregnancy,[47] and aberrant DNA methylation is implicated 
in the pathophysiology of GDM. Altered DNA methylation patterns 
have been demonstrated in maternal blood, placental tissue and 
cord blood of GDM-complicated pregnancies, thus supporting its 
potential as biomarkers.[48-53]
Wu et al.[54] demonstrated that two genes, Hook microtubule-
tethering protein 2 (HOOK2) and retinol dehydrogenase 12 (RDH12), 
are differentially methylated in placenta and whole blood of women 
with GDM. Interestingly, the changes in methylation status of these 
genes in whole blood occurred prior to the development of GDM, 
supporting their potential as screening biomarkers of GDM. In a 
study investigating maternal and cord blood in pregnant women 
and their offspring, Kang et al.[55] identified 200 genes that were 
differentially methylated in women with GDM compared with 
controls. Conversely, our recent study[56] showed no differences in 
global DNA methylation between pregnant women with GDM and 
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those with normoglycaemia in SA. Global DNA methylation is a 
robust marker for overall genomic methylation; therefore, our failure 
could be due to subtle methylation differences between GDM and 
control groups. Perhaps, a more targeted approach using genome-
wide gene-specific DNA methylation should be considered. Together, 
these studies show that altered DNA methylation in different 
biological material plays an important role in the pathophysiology of 
GDM and offers opportunities as biomarkers. 
Another epigenetic mechanism widely explored as a biomarker 
for GDM,[57] i.e. miRNAs, has been shown to post-transcriptionally 
regulate genes involved in diverse biological processes, including 
glucose homeostasis.[58] Placental miRNA expression reflects 
metabolic adaptation, with aberrant expression observed during 
GDM. Interestingly, the expression of many of these altered miRNAs 
is mirrored in serum or plasma, thus offering potential as biomarkers 
for GDM. Zhao et al.[59] reported that the expression of miR-29a 
and miR-222, miRNAs that are involved in insulin sensitivity, 
glucose homeostasis and beta-cell function, are decreased in serum 
of Chinese women with GDM compared with pregnant women 
without GDM. Pheiffer et al.[60] similarly reported that the expression 
of miR-222 is decreased in the serum of SA women with GDM. 
They also reported the decreased expression of miR-20a, which 
was a significant predictor of GDM. Conversely, Tagoma et al.[61] 
reported increased expression of plasma-derived miR-222 in Finnish 
women with GDM compared with controls, while miR-20a was 
increased in Chinese women with GDM compared with controls.[62] 
Furthermore, many studies have demonstrated that placenta-specific 
miRNAs are altered in pregnancy complications, such as pre-
eclampsia, macrosomia, preterm delivery, pregnancy loss and small-
for-gestational-age babies, which further supports the use of miRNAs 
as predictive biomarkers for adverse pregnancy outcomes.[63,64] 
GDM creates an abnormal intrauterine environment that negatively 
affects the long-term health of offspring, possibly through in utero 
programming of epigenetic mechanisms such as DNA methylation 
and miRNAs.[52,65-67] Using genome-wide methylation analysis, 
Heartle et al.[52] identified 65 CpG sites associated with 52 genes that 
were differentially methylated in fetal cord blood from GDM and 
control pregnancies. Of these, 5 candidate genes that play a role in 
metabolic pathways associated with oxidative damage, cardiovascular 
complications, glucose and amino-acid metabolisms and adipocyte 
differentiation were validated. El Hajj et al.[65] showed gene-specific 
methylation changes in the maternally imprinted MESH gene and the 
non-imprinted glucocorticoid receptor (NR3C1) gene in both cord 
blood and placental tissue of GDM groups compared with controls. 
Recently, altered miRNA expression in the cord blood of offspring 
was shown to be associated with fetal complications.[66] Tryggestad et al.[67] 
indicated that 7 miRNAs were upregulated in human umbilical vein 
endothelial cells from infants born to mothers with GDM. Despite 
their stability, relative ease of quantification and affordability, DNA 
methylation and miRNAs present several challenges that hinder 
their reproducibility across studies. Future research should explore 
risk-scoring systems that can be used to combine molecular markers 
with maternal risk indicators to develop a clinical prediction tool for 
GDM. 
Screening and diagnosis in South 
Africa
The four most common diagnostic criteria used in SA are the 
IADPSG, NICE, American College of Obstetricians and Gynecologists 
(ACOG) and WHO 1999 criteria (Table 1). In 2017, the Society for 
Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 
endorsed the IADPSG criteria and universal testing of all pregnant 
women.[68] However, the IADPSG criteria are still being debated, as 
many clinicians consider these unfeasible in low- and middle-income 
countries such as SA. Their view is that it leads to overdiagnosis, and 
places a high demand on costs, workload and resources. Therefore, 
many local and regional health facilities continue to use risk-factor, 
selective IADPSG, NICE, ACOG or WHO 1999 criteria (Table 2).[69]
Current perspectives and future 
recommendations 
• Early screening and diagnosis of GDM improve health outcomes. 
• Although the OGTT is the gold standard for diagnosis, there is no 
consensus, and GDM diagnosis is not standardised.
• Novel screening and diagnostic strategies offer potential as 
biomarkers of GDM, but are yet to achieve clinical applicability.
Table 2. Current approach to gestational diabetes mellitus screening at select academic centres in South Africa* 
Institution Testing Diagnostic criteria Level of screening
Glucometer v. 
laboratory GDM management†
UP Selective‡ WHO 2013 Clinic and hospital Glucometer and
laboratory
Tertiary hospital
WITS Selective‡ NICE Hospital Laboratory Tertiary hospital
UKZN Selective‡ and 
universal§ for  
R K Khan Hospital 
(Indian)
WHO 2013 Hospital Laboratory Tertiary hospital
UCT Selective‡ WHO 2013 Hospital Laboratory Tertiary hospital
SU Selective‡ NICE Clinic and hospital Glucometer Tertiary hospital
UFS Selective‡ IADPSG/WHO 2013 Clinic and hospital Glucometer and 
laboratory
Tertiary hospital
SMU Selective‡ Modified WHO¶ Hospital Laboratory Tertiary hospital
Walter Sisulu Selective‡ WHO 2013 Hospital Laboratory Tertiary hospital
GDM = gestational diabetes mellitus; UP = University of Pretoria; WHO = World Health Organization; WITS = University of the Witwatersrand;  
NICE = National Institute for Health and Care Excellence; UKZN = University of KwaZulu-Natal; UCT = University of Cape Town; SU = Stellenbosch University;  
UFS = University of the Free State; IADPSG = International Association of Diabetes in Pregnancy Study Groups; SMU = Sefako Makgatho Health Sciences University.
*The details of this table were communicated with individuals of the respective institutes between September and November 2018.
†All women with a positive oral glucose tolerance test are referred to a tertiary hospital for management of GDM.
‡Based on risk factors.
§All women receive an oral glucose tolerance test.
¶The institute’s own version of the WHO criteria, which have not yet been published.
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• Future longitudinal studies across SA are required to assess the 
risks and benefits of diagnostic criteria and pregnancy outcomes.
• Experts are needed to establish and co-ordinate such initiatives 
and to make evidence-based recommendations on GDM screening 
and diagnosis.
Conclusions
We have highlighted the varied screening and diagnostic strategies 
currently employed in SA. Although universal screening and 
diagnosis of GDM are widely advocated as a strategy to promote 
appropriate treatment and improve pregnancy outcomes, it is not 
feasible in many low- and middle-income countries, resulting in 
many countries using risk factor-based selective screening. The lack 
of uniform GDM screening and diagnostic criteria and variation in 
clinical practice negatively affect maternal and child health. There is 
limited evidence to support one approach over the other. There is a 
need for longitudinal studies across SA to investigate the association 
between their diagnostic criteria and pregnancy outcomes, as well as 
long-term outcomes in mothers and their offspring. We recommend 
that an SA diabetes-in-pregnancy study group, comprising interested 
obstetricians, physicians, endocrinologists, public health specialists, 
dieticians and scientists, be established to co-ordinate such initiatives 
and to make evidence-based recommendations on GDM screening, 
diagnosis and management. 
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